Hyperhomocysteinemia-related cerebral venous thrombosis;Trombosis venosa cerebral en relación con la hiperhomocisteinemia

Revista de Neurologia

Volumn 37, Issue 11, 2003, Pages 1040-1043

  Fernandez Moreno M C ^a,c   Castilla Guerra, L ^b   Castella Murillo, A ^a   Cueli Rincon B ^a   Fernandez Bolanos R ^a   Gutierrez Tous R ^a   Jimenez Hernandez M D ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL DE LA MERCED   (Spain)

^c NONE   (Spain)

Author keywords

Cerebral venous thrombosis; Folic acid; Hypercoagulability; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase; Oral contraceptives

Indexed keywords

ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; FOLIC ACID; HOMOCYSTEINE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN VEIN; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEADACHE; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IMMUNOLOGICAL PROCEDURES; MAGNETIC RESONANCE ANGIOGRAPHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPILLEDEMA; RISK FACTOR; VEIN THROMBOSIS; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 0345861807     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3711.2003201     Document Type: Article

References (15)

1. Cattaneo M. Hyperhomocysteinemia and thrombosis. Lipids 2001; 36: 13-26.
2. Shimizu H, Kiyohara Y, Kato I, Tanizaki Y, Ueno H, Kimura Y, et al. Plasma homocysteine concentrations and the risk of subtypes of scerebral infarction. The Hisayama study. Cerebrovasc Dis 2002; 13: 9-15.
3. Hankey GJ, Eikelboom JW. Homocysteine and stroke. Curr Opin Neurol 2001; 14: 95-102.
4. Madonna P, De Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefiece G, et al. Hyperhomocysteinemia and others inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002; 33: 1452-3.
5. Den Heijer M, Keijzer MB. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med 2001; 39: 710-3.
6. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscler Thromb Vasc Biol 1994; 14: 1080-3.
7. Hiller CE, Collins PW, Bowen DJ, Bowley S, Wiles CM. Inherited prothrombotic risk factors and cerebral venous thrombosis. QJM 1998; 91: 677-80.
8. Sánchez-Marín Grasa JM, Latorre A, Montañés MA, García-Erce JA, Torres M, et al. Hipercoagulabilidad hereditaria y adquirida en pacientes con trombosis venosa cerebral. Neurología 2002; 17: 405-9.
9. Stolz E, Kemkes-Matthes B, Pötzsch B, Hahn M, Kraus J, Wirbartz A, et al. Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. Acta Neurol Scand 2000; 102: 31-6.
10. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveria S, Plomaritoglou A, et al. Homocysteine, MTHFR 677C-T polymorphism, and risk of ischemic stroke. Neurology 2002; 59: 529-36.
11. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on casuality from a meta-analysis. BMJ 2002; 325: 1202-6.
12. Godsland IF, Winkler U, Lidegaard O, Crook D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs 2000; 60: 721-869.
13. Souto JC, Coll I, Llobet D, del Río E, Oliver A, Mateo J, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-9.
14. Kelly PJ, Furie KL. Management and prevention of stroke associated with elevated homocysteine. Curr Treat Options Cardiovasc Med 2002; 4: 363-71.
15. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894-8.